Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 1, 2002, Pages 115-117

  Basso, Stéphanie ^a   Solas, Caroline ^a   Quinson, Anne Marie ^a   Ravaux, Isabelle ^a   Poizot Martin, Isabelle ^a   Bacconier, J ^a   Durand, Alain ^a   Lacarelle, Bruno ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; GLYCOPROTEIN P; LOPINAVIR; RITONAVIR;

ADULT; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; LETTER; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE; TREATMENT OUTCOME;

EID: 0036740266     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200209010-00015     Document Type: Letter

References (17)

1. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
2. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304.
3. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-94.
4. Hsu A, Granneman G, Bertz R. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-91.
5. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-169.
6. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
7. Jayewardene AL, Zhu F, Aweeka FT, et al. Simple highperformance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J Chromatogr B 1998;707:203-11.
8. Goujard C, Meynard JL, Choudet N, et al. Study PROF1004: steady-state pharmacokinetics of amprenavir 600mg TWICE DAILY and ritonavir 100mg TWICE DAILY with or without NNRTI in HIV-1 infected patients [abstract 268]. 5th. International Congress on Drug therapy in HIV Infection, Glasgow, October 2000.
9. Wood R, Trepo C, Livrozet JM, et al. Enhancement of pharmacokinetic parameters of amprenavir when combined with low dose ritonavir (APV 600 mg/RTV 100 mg TWICE DAILY) and preliminary efficacy results [abstract 283]. 5th. International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000.
10. Taburet AM, Paci-Bonaventure S, Goujard C, et al. Therapeutic drug monitoring of amprenavir combined with ritonavir as salvage therapy in HIV-1 infected patients [abstract PeB 3305]. 13th International AIDS Conference, Durban, July 2000.
11. Amprenavir. [package insert]. Research Triangle Park, NC: Glaxo Wellcome 2000.
12. Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agent Chemother 2001;45:30-37.
13. Gathe J, Sax P, Beeler L, et al. Minimal pharmacokinetic interaction between amprenavir and lopinavir [abstract E-18]. 11th Symposium on HIV Infection, Toulon, June 2001.
14. Stein AJ, Brothers CH. Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV. Clin Ther 2001;23:513-15.
15. Peytavin G, Lamotte C, Duval X, et al. Amprenavir plasma concentrations are dramatically decreased by association with ABT378/r in HIV-infected patients [abstract 1.14]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, April 2001.
16. Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001;29:754-60.
17. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-42.